Sanofi gains EU approval recommendation for Scarlisa subcutaneous version

What: Sanofi has received a positive EU approval recommendation for its subcutaneous version of Scarlisa.
Why: The approval is expected to expand treatment options for patients with mantle cell lymphoma.
Signal: The EU's CHMP has recommended approval for the subcutaneous formulation of Scarlisa.
Target: The new formulation aims to offer a more convenient dosing option for patients.
Risk: The approval process has not been without controversy, with some concerns raised about the drug's safety profile.